首页> 外文期刊>International Journal for Parasitology: Drugs and Drug Resistance >Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice
【24h】

Di-cationic arylimidamides act against Neospora caninum tachyzoites by interference in membrane structure and nucleolar integrity and are active against challenge infection in mice

机译:双阳离子芳基酰胺类化合物通过干扰膜结构和核仁完整性来对抗犬新孢子虫速殖子,并且对小鼠的攻击性感染具有活性

获取原文
       

摘要

Neospora caninum is considered to be the main cause of bovine abortion in Europe and the USA, leading to considerable financial impact. Losses are caused directly by abortions or indirectly through breeding of calves with impaired viability. Due to the lack of effective chemotherapy against bovine neosporosis, there is a need to develop new anti-protozoal compounds, which would either eliminate the parasite or avoid its transmission. In order to identify compounds of interest, the in vitro activities of 41 di-cationic pentamidine derivatives were studied employing a transgenic N. caninum clone expressing beta-galactosidase as a reporter gene. The arylimidamide DB745, previously shown to be highly active against Leishmania donovani in vitro and in vivo, appeared as the most promising compound, with an IC"5"0 of 80nM in 3-day growth assays and severely affecting both host cell invasion as well as intracellular proliferation. TEM of intracellular tachyzoites identified distinct alterations related to the nucleolus and the nuclear and cellular membrane. Long-term growth assays showed that DB745 acted parasiticidal upon the Nc-Liv isolate, but not against the Nc-1 isolate of N. caninum. In vivo studies in N. caninum (Nc-1 isolate) infected mice showed that daily intraperitoneal application of DB745 for a period of 14days resulted in a decreased number of clinically affected animals, and lower cerebral parasite burdens in DB745-treated mice compared to non-treated mice. These results illustrate the potential of dicationic arylimidamides for the treatment of N. caninum infections.
机译:在欧洲和美国,犬新孢子虫被认为是牛流产的主要原因,导致了巨大的经济影响。损失是由堕胎直接造成的,或者是由于生存能力受损的小牛的繁殖间接造成的。由于缺乏针对牛新孢子虫病的有效化学疗法,因此需要开发新的抗原生动物化合物,其可以消除寄生虫或避免其传播。为了鉴定目标化合物,使用表达β-半乳糖苷酶作为报告基因的转基因猪链球菌研究了41种双阳离子戊tam衍生物的体外活性。先前显示在体外和体内对利什曼原虫高活性的芳基酰胺DB745似乎是最有前途的化合物,在3天的生长试验中IC“ 5” 0为80nM,并且还严重影响了宿主细胞的侵袭作为细胞内增殖。胞内速殖子的TEM鉴定出与核仁以及核和细胞膜有关的明显变化。长期生长试验表明,DB745对Nc-Liv分离株具有杀寄生虫作用,但对犬新孢子虫的Nc-1分离株无杀虫作用。在犬新孢子虫(Nc-1分离株)感染小鼠中进行的体内研究表明,每天腹膜内应用DB745持续14天可导致受临床影响的动物数量减少,与未使用DB745的小鼠相比,DB745治疗的小鼠脑部寄生虫负担降低治疗的小鼠。这些结果说明了阿利米胺类药物治疗犬新孢子虫感染的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号